International Myeloma Working Group recommendations for global myeloma care

H. Ludwig; J. S. Miguel; M. A. Dimopoulos; A. Palumbo; R. Garcia Sanz; R. Powles; S. Lentzsch; W. Ming Chen; J. Hou; A. Jurczyszyn; K. Romeril; R. Hajek; E. Terpos; K. Shimizu; D. Joshua; V. Hungria; A. Rodriguez Morales; D. Ben-Yehuda; P. Sondergeld; E. Zamagni; B. Durie

doi:10.1038/leu.2013.293

International Myeloma Working Group recommendations for global myeloma care

H. Ludwig^*, J. S. Miguel, M. A. Dimopoulos, A. Palumbo, R. Garcia Sanz, R. Powles, S. Lentzsch, W. Ming Chen, J. Hou, A. Jurczyszyn, K. Romeril, R. Hajek, E. Terpos, K. Shimizu, D. Joshua, V. Hungria, A. Rodriguez Morales, D. Ben-Yehuda, P. Sondergeld, E. ZamagniB. Durie

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

158 Scopus citations

Abstract

Recent developments have led to remarkable improvements in the assessment and treatment of patients with multiple myeloma (MM). New technologies have become available to precisely evaluate the biology and extent of the disease, including information about cytogenetics and genetic abnormalities, extramedullary manifestations and minimal residual disease. New, more effective drugs have been introduced into clinical practice, which enable clinicians to significantly improve the outcome of patients but also pose new challenges for the prevention and management of their specific side effects. Given these various new options and challenges, it is important to identify the minimal requirements for diagnosis and treatment of patients, as access to the most sophisticated advances may vary depending on local circumstances. Here, we propose the minimal requirements and possible options for diagnosis, monitoring and treatment of patients with multiple myeloma.

Original language	English
Pages (from-to)	981-992
Number of pages	12
Journal	Leukemia
Volume	28
Issue number	5
DOIs	https://doi.org/10.1038/leu.2013.293
State	Published - May 2014
Externally published	Yes

Bibliographical note

Funding Information:
We wish to acknowledg the secretarial assistance of Raphaela Oswald and the support by the International Myeloma Foundation and Austrian Forum against Cancer.

Keywords

global perspective
management of myeloma-related side effects
myeloma care

Access to Document

10.1038/leu.2013.293

Cite this

Ludwig, H., Miguel, J. S., Dimopoulos, M. A., Palumbo, A., Garcia Sanz, R., Powles, R., Lentzsch, S., Ming Chen, W., Hou, J., Jurczyszyn, A., Romeril, K., Hajek, R., Terpos, E., Shimizu, K., Joshua, D., Hungria, V., Rodriguez Morales, A., Ben-Yehuda, D., Sondergeld, P., ... Durie, B. (2014). International Myeloma Working Group recommendations for global myeloma care. Leukemia, 28(5), 981-992. https://doi.org/10.1038/leu.2013.293

@article{5748d045fa354ce39301b5d5c9363507,

title = "International Myeloma Working Group recommendations for global myeloma care",

abstract = "Recent developments have led to remarkable improvements in the assessment and treatment of patients with multiple myeloma (MM). New technologies have become available to precisely evaluate the biology and extent of the disease, including information about cytogenetics and genetic abnormalities, extramedullary manifestations and minimal residual disease. New, more effective drugs have been introduced into clinical practice, which enable clinicians to significantly improve the outcome of patients but also pose new challenges for the prevention and management of their specific side effects. Given these various new options and challenges, it is important to identify the minimal requirements for diagnosis and treatment of patients, as access to the most sophisticated advances may vary depending on local circumstances. Here, we propose the minimal requirements and possible options for diagnosis, monitoring and treatment of patients with multiple myeloma.",

keywords = "global perspective, management of myeloma-related side effects, myeloma care",

author = "H. Ludwig and Miguel, {J. S.} and Dimopoulos, {M. A.} and A. Palumbo and {Garcia Sanz}, R. and R. Powles and S. Lentzsch and {Ming Chen}, W. and J. Hou and A. Jurczyszyn and K. Romeril and R. Hajek and E. Terpos and K. Shimizu and D. Joshua and V. Hungria and {Rodriguez Morales}, A. and D. Ben-Yehuda and P. Sondergeld and E. Zamagni and B. Durie",

note = "Funding Information: We wish to acknowledg the secretarial assistance of Raphaela Oswald and the support by the International Myeloma Foundation and Austrian Forum against Cancer.",

year = "2014",

month = may,

doi = "10.1038/leu.2013.293",

language = "אנגלית",

volume = "28",

pages = "981--992",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "5",

}

Ludwig, H, Miguel, JS, Dimopoulos, MA, Palumbo, A, Garcia Sanz, R, Powles, R, Lentzsch, S, Ming Chen, W, Hou, J, Jurczyszyn, A, Romeril, K, Hajek, R, Terpos, E, Shimizu, K, Joshua, D, Hungria, V, Rodriguez Morales, A, Ben-Yehuda, D, Sondergeld, P, Zamagni, E & Durie, B 2014, 'International Myeloma Working Group recommendations for global myeloma care', Leukemia, vol. 28, no. 5, pp. 981-992. https://doi.org/10.1038/leu.2013.293

TY - JOUR

T1 - International Myeloma Working Group recommendations for global myeloma care

AU - Ludwig, H.

AU - Miguel, J. S.

AU - Dimopoulos, M. A.

AU - Palumbo, A.

AU - Garcia Sanz, R.

AU - Powles, R.

AU - Lentzsch, S.

AU - Ming Chen, W.

AU - Hou, J.

AU - Jurczyszyn, A.

AU - Romeril, K.

AU - Hajek, R.

AU - Terpos, E.

AU - Shimizu, K.

AU - Joshua, D.

AU - Hungria, V.

AU - Rodriguez Morales, A.

AU - Ben-Yehuda, D.

AU - Sondergeld, P.

AU - Zamagni, E.

AU - Durie, B.

N1 - Funding Information: We wish to acknowledg the secretarial assistance of Raphaela Oswald and the support by the International Myeloma Foundation and Austrian Forum against Cancer.

PY - 2014/5

Y1 - 2014/5

N2 - Recent developments have led to remarkable improvements in the assessment and treatment of patients with multiple myeloma (MM). New technologies have become available to precisely evaluate the biology and extent of the disease, including information about cytogenetics and genetic abnormalities, extramedullary manifestations and minimal residual disease. New, more effective drugs have been introduced into clinical practice, which enable clinicians to significantly improve the outcome of patients but also pose new challenges for the prevention and management of their specific side effects. Given these various new options and challenges, it is important to identify the minimal requirements for diagnosis and treatment of patients, as access to the most sophisticated advances may vary depending on local circumstances. Here, we propose the minimal requirements and possible options for diagnosis, monitoring and treatment of patients with multiple myeloma.

AB - Recent developments have led to remarkable improvements in the assessment and treatment of patients with multiple myeloma (MM). New technologies have become available to precisely evaluate the biology and extent of the disease, including information about cytogenetics and genetic abnormalities, extramedullary manifestations and minimal residual disease. New, more effective drugs have been introduced into clinical practice, which enable clinicians to significantly improve the outcome of patients but also pose new challenges for the prevention and management of their specific side effects. Given these various new options and challenges, it is important to identify the minimal requirements for diagnosis and treatment of patients, as access to the most sophisticated advances may vary depending on local circumstances. Here, we propose the minimal requirements and possible options for diagnosis, monitoring and treatment of patients with multiple myeloma.

KW - global perspective

KW - management of myeloma-related side effects

KW - myeloma care

UR - http://www.scopus.com/inward/record.url?scp=84899915546&partnerID=8YFLogxK

U2 - 10.1038/leu.2013.293

DO - 10.1038/leu.2013.293

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???

C2 - 24177258

AN - SCOPUS:84899915546

SN - 0887-6924

VL - 28

SP - 981

EP - 992

JO - Leukemia

JF - Leukemia

IS - 5

ER -

International Myeloma Working Group recommendations for global myeloma care

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this